Roberta Gualtierotti: How Do Sex and Gender Influence VTE in Patients with Cancer?
Roberta Gualtierotti, Associate Professor of Internal Medicine at the University of Milan, posted on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Cancer-associated thrombosis (CAT) remains one of the leading causes of morbidity and mortality in oncology.
Yet one important dimension of risk is still insufficiently explored: sex and gender differences.
How do sex and gender influence venous thromboembolism (VTE) in patients with cancer?
Men generally show a higher overall incidence of cancer-associated VTE.
- Women may experience earlier thrombotic events, often related to anticancer therapies.
- Biological differences in coagulation and inflammation may contribute to these patterns, although the underlying mechanisms are still not fully understood.
- Sex-related disparities also appear in treatment complications, including bleeding risk and abnormal uterine bleeding in anticoagulated women of reproductive age.
- In hematologic malignancies, evidence on sex differences in thrombosis remains limited and inconsistent.
In addition, gender-related inequalities in clinical trial participation still affect the interpretation of available data.
Overall, current evidence supports sex as a clinically relevant modifier of cancer-associated thrombosis risk.
Advancing research that systematically integrates sex- and gender-informed analyses and sex-stratified reporting will be essential to improve mechanistic understanding and support precision medicine in thrombosis and oncology.”
Title: Sex Differences in Cancer-Associated Thrombosis
Authors: Andrea Giachi, Davide Santagata, Addolorata Truma, Andrea Artoni, Paolo Bucciarelli, Luca Valenti, Cihan Ay, Roberta Gualtierotti
Read the Full Article on International Journal of Molecular Sciences

Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease